By Dr Oliver Jones Key points: In FAME 3, PCI failed to meet noninferiority versus CABG for composite MACE in three-vessel CAD patients without severe…
View More FAME 3 published and guideline updates: PCI vs CABG in multivessel disease debate continues.
By Dr Megha Agarwal A new study1 has been published in JAMA evaluating whether there is a difference in risk of major ischemic or haemorrhagic…
View More At loggerheads: rivaroxaban vs apixaban
By Dr Aswin Babu PRAGUE-17 was a multi-centre, prospective, randomised, non-inferiority trial assessing the efficacy of left atrial appendage closure (LAAC) when compared to direct…
View More A win for left atrial appendage occlusion devices
By Joe Cuthbert The recommendations for clinicians from ESC HF Guidelines 2021 most likely to impact management of the heart failure patient: Aim to start…
View More European Society of Cardiology Heart Failure Guidelines 2021: What should we be doing in current practice?
By Andre Briosa e Gala Take Home Messages AF may go undetected in patients until they experience a complication, such as an AF-related stroke. Early…
View More AF screening and thromboembolic risk: How much AF is significant?
By John Graby Take Home Messages CVD remains a leading cause of morbidity and mortality suggesting a need for improving its management Exercise is important…
View More Exercise as a treatment: do we talk about it enough in Hypertension Management?
By Dr. Timothy Swinn AcronymsEEA- European Economic AreaOR- Odds ratioCI- Confidence interval A study published in Heart earlier this week shed light on the extensive…
View More Bullying in UK cardiology: 1-in-10 trainees affected
By Dr. Jonathan Shurlock Grubic et al. systematically reviewed the available literature exploring exercise-related sudden cardiac arrest (SCA). Studies eligible for inclusion were observational studies…
View More Exercise-related cardiac arrest associated with higher rate of shockable rhythm
By Dr Megha Agarwal P2Y12 receptor antagonists such as clopidogrel, ticagrelor, prasugrel are used in acute coronary syndrome for their anti-platelet properties. To date, no…
View More Bentracimab: A potential new reversal agent for Ticagrelor
Cardiac Crossroads has been produced by the British Junior Cardiologists’ Association (BJCA) in collaboration with the British Heart Rhythm Society (BHRS) and the British Society…
View More BJCA Cardiac Crossroads Seminar 1: Hot topics in Arrhythmia management and Heart Failure